MannKind (MNKD) Competitors

MannKind (NASDAQ:MNKD) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking.

Does the media favor MNKD or MDGL?

In the previous week, Madrigal Pharmaceuticals had 23 more articles in the media than MannKind. MarketBeat recorded 26 mentions for Madrigal Pharmaceuticals and 3 mentions for MannKind. Madrigal Pharmaceuticals' average media sentiment score of 0.49 beat MannKind's score of 0.40 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, MNKD or MDGL?

MannKind has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500.

Do insiders and institutionals have more ownership in MNKD or MDGL?

49.5% of MannKind shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 3.0% of MannKind shares are held by insiders. Comparatively, 22.8% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Do analysts prefer MNKD or MDGL?

MannKind presently has a consensus target price of $9.07, indicating a potential upside of 50.94%. Madrigal Pharmaceuticals has a consensus target price of $351.67, indicating a potential upside of 19.76%. Given MannKind's stronger consensus rating and higher probable upside, equities analysts plainly believe MannKind is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Which has higher earnings and valuation, MNKD or MDGL?

MannKind has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$267.20M	6.20	-$11.94M	$0.07	85.86
Madrigal Pharmaceuticals	N/A	N/A	-$373.63M	-$25.08	-11.71

Does the MarketBeat Community favor MNKD or MDGL?

MannKind received 123 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. However, 67.80% of users gave Madrigal Pharmaceuticals an outperform vote while only 60.12% of users gave MannKind an outperform vote.

Company	Underperform	Outperform
MannKind	Outperform Votes 582 60.12%	Underperform Votes 386 39.88%
Madrigal Pharmaceuticals	Outperform Votes 459 67.80%	Underperform Votes 218 32.20%

Is MNKD or MDGL more profitable?

MannKind has a net margin of 8.07% compared to Madrigal Pharmaceuticals' net margin of 0.00%. MannKind's return on equity of -17.74% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	8.07%	-17.74%	8.68%
Madrigal Pharmaceuticals	N/A	-71.78%	-53.25%

Summary

MannKind beats Madrigal Pharmaceuticals on 12 of the 18 factors compared between the two stocks.